MedTrace Logo

Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients

NCT05675748 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-01-13

No results posted yet for this study

Summary

This study was a multicenter, non-intervention, real world study. To evaluate the efficacy and safety of azvudine in nursing homes with mild/common COVID-19 patients. The primary outcome measure was the proportion of patients with severe/critical illness within 28 days.

Conditions

Interventions

DRUG

Azvudine

Azvudine tablets are taken orally 5mg daily for a maximum of 14 days

Sponsors & Collaborators

  • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

    collaborator INDUSTRY

  • Huashan Hospital

    collaborator OTHER

  • Shanghai Henlius Biotech

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-15
Primary Completion
2023-03-15
Completion
2023-04-15

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05675748 on ClinicalTrials.gov